ABVC Biopharma Inc (ABVC) Financials

$1.01

$0.03 (3.06%)

As on 14-Sep-2026 14:34EDT

Market cap

$26 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	0.80	0.51	0.15	0.97	0.36
Cost of Revenue	0.31	0.50	0.00	0.30	0.29	0.01
Gross Profit	-0.09	0.80	0.51	-0.15	0.68	0.35
Operating Expenses	6.52	7.15	5.21	6.62	15.80	12.06
Operating Profit (EBIT)	-7.31	-7.15	-4.71	-6.77	-15.11	-11.71
Other Income	--	--	--	--	--	--
Profit before Tax	-8.40	-8.35	-5.37	-8.02	-15.51	-11.21
Provision for Tax	-2.30	0.02	-0.11	0.26	0.80	0.83
Profit after Tax (Net Income)	-7.90	-7.91	-4.90	-7.79	-16.42	-12.84
Minority Interest	0.49	0.47	0.36	0.39	-0.11	-0.80
Consolidated Profit	--	--	--	--	-16.42	-12.84

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	10.29	11.11	1.23	1.55	4.45	8.84
Minority Interest	0.49	--	--	--	--	--
Non-Current Liabilities	1.44	1.60	0.26	0.43	0.80	1.14
Current Liabilities	5.69	6.16	6.56	6.10	5.54	3.69
Total Liabilities	25.10	21.06	7.54	7.78	10.93	13.70

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	18.99	18.56	5.36	6.13	7.95	6.04
Current Assets	0.41	2.50	2.18	1.66	2.99	7.65
Total Assets	25.10	21.06	7.54	7.78	10.93	13.70
Total Debt*	1.76	3.47	3.20	2.77	3.41	3.34
Net Current Assets	-5.28	-3.66	-4.38	-4.28	-2.83	5.93

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-2.99	-1.81	-4.19	-7.40	-7.60
Cash Flow from Investing Activities	--	-1.21	--	-0.36	-1.72	-0.81
Cash from Financing Activities	--	4.64	1.98	3.87	4.01	10.00
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.33	-0.34	-0.37	-1.11	-5.11	-4.94
Cash EPS ($)	-0.29	-0.32	-0.36	-1.10	-5.11	-4.94
Adjusted Book Value ($)	0.40	0.48	0.09	0.22	1.39	3.41
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.13	-0.14	-0.60	-2.30	-2.93
Free Cash Flow per Share ($)	--	-0.13	-0.14	-0.60	-2.34	-2.93

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-83.18	-112.03	-127.77	-163.81	-100.49
ROE (%)	-69.24	-128.20	-352.69	-259.29	-247.03	-166.28
ROA (%)	-33.02	-55.30	-63.99	-83.21	-133.35	-90.21
EBIT Margin (%)	--	-997.16	-891.64	-4,402.79	-1,569.49	-3,087.05
Net Margin (%)	--	-993.60	-962.12	-5,109.26	-1,693.50	-3,608.47
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	0.56	2.34	-0.84	1.73	-0.26
EBIT Growth (%)	-160.15	-74.68	32.30	55.91	-38.58	-5.52
Net Profit Growth (%)	-143.83	-61.30	37.05	52.58	-27.92	-31.13
EPS Growth (%)	-64.94	0.09	0.66	0.78	-0.03	0.01
Book Value Growth (%)	-2.14	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-6.26	-1.58	-1.05	-0.12	-0.69
Price / Book Value	2.55	4.46	6.32	5.25	0.45	1.00
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.90	-7.03	-2.31	-1.60	-0.26	-0.57
Close Price ($)	1.58	2.13	0.59	1.16	6.25	33.90
High Price ($)	5.48	5.48	2.18	18.70	39.40	299.50
Low Price ($)	0.90	0.40	0.41	0.67	5.00	19.50
Market Cap ($ Cr)	26.12	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.31	2.61	1.78	0.77	0.38
Short term debt to equity ratio	0.03	0.17	2.42	1.52	0.59	0.25
Current Ratio	0.07	0.41	0.33	0.27	0.54	2.07
Quick Ratio	0.07	--	--	--	0.30	2.07
Interest Coverage	-53.09	-19.08	-5.50	-5.11	-51.78	-48.34

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	95.91	226.66	498.30	141.22	119.76
Asset Turnover	--	0.06	0.07	0.02	0.08	0.02
Receivable days	--	440.17	686.15	2,550.80	338.13	731.68
Inventory Days	--	--	--	1,579.89	849.59	-29,218.38
Payable days	--	--	54,067.53	136.58	--	827.45
Cash Conversion Cycle	--	--	--	3,994.11	1,187.73	-29,314.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.